Combining Wireless Technology and Behavioral Economics to Engage Patients (WiBEEP) with cardiometabolic disease: a pilot study.
Blood pressure
Diabetes
Diet
Exercise
Text messages
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
09
2018
accepted:
04
01
2019
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
25
1
2019
Statut:
epublish
Résumé
The long-term management of cardiometabolic diseases, such as type 2 diabetes and hypertension, is complex and can be facilitated by supporting patient-directed behavioral changes. The concurrent application of wireless technology and personalized text messages (PTMs) based on behavioral economics in managing cardiometabolic diseases, although promising, has not been studied. The aim of this pilot study was to evaluate the feasibility and acceptability of the concurrent application of wireless home blood pressure (BP) monitoring (as an example of "automated hovering") and PTMs (as an example of "nudging") targeting pharmacotherapy and lifestyle habits in patients with cardiometabolic disease (type 2 diabetes and/or hypertension). The Wireless Technology and Behavioral Economics to Engage Patients (WiBEEP) with cardiometabolic disease study was a single-arm, open-label, 7-week-long pilot study in 12 patients (mean age 58.5 years) with access to a mobile phone. The study took place at Tufts Medical Center (Boston, MA) between March and September 2017. All patients received PTMs; nine patients received wireless home BP monitoring. At baseline, patients completed questionnaires to learn about their health goals and to assess medication adherence; at the end of week 7, all patients completed questionnaires to evaluate the feasibility and acceptability of the intervention and assess medication adherence. Hemoglobin A1c was ascertained from data collected during routine clinical care in 7 patients with available data. The majority of patients reported the text messages to be easy to understand (88%) and appropriate in frequency (71%) and language (88%). All patients reported BP monitoring to be useful. Mean arterial pressure was lower at the end-of-study compared to baseline (- 3.4 mmHg [95% CI, - 5 to - 1.8]. Mean change in hemoglobin A1c was - 0.31% [95% CI, - 0.56 to - 0.06]. Among patients with cardiometabolic disease, the combination of wireless BP monitoring and lifestyle-focused text messaging was feasible and acceptable. Larger studies will determine the long-term effectiveness of such an approach.
Sections du résumé
BACKGROUND
BACKGROUND
The long-term management of cardiometabolic diseases, such as type 2 diabetes and hypertension, is complex and can be facilitated by supporting patient-directed behavioral changes. The concurrent application of wireless technology and personalized text messages (PTMs) based on behavioral economics in managing cardiometabolic diseases, although promising, has not been studied. The aim of this pilot study was to evaluate the feasibility and acceptability of the concurrent application of wireless home blood pressure (BP) monitoring (as an example of "automated hovering") and PTMs (as an example of "nudging") targeting pharmacotherapy and lifestyle habits in patients with cardiometabolic disease (type 2 diabetes and/or hypertension).
METHODS
METHODS
The Wireless Technology and Behavioral Economics to Engage Patients (WiBEEP) with cardiometabolic disease study was a single-arm, open-label, 7-week-long pilot study in 12 patients (mean age 58.5 years) with access to a mobile phone. The study took place at Tufts Medical Center (Boston, MA) between March and September 2017. All patients received PTMs; nine patients received wireless home BP monitoring. At baseline, patients completed questionnaires to learn about their health goals and to assess medication adherence; at the end of week 7, all patients completed questionnaires to evaluate the feasibility and acceptability of the intervention and assess medication adherence. Hemoglobin A1c was ascertained from data collected during routine clinical care in 7 patients with available data.
RESULTS
RESULTS
The majority of patients reported the text messages to be easy to understand (88%) and appropriate in frequency (71%) and language (88%). All patients reported BP monitoring to be useful. Mean arterial pressure was lower at the end-of-study compared to baseline (- 3.4 mmHg [95% CI, - 5 to - 1.8]. Mean change in hemoglobin A1c was - 0.31% [95% CI, - 0.56 to - 0.06].
CONCLUSIONS
CONCLUSIONS
Among patients with cardiometabolic disease, the combination of wireless BP monitoring and lifestyle-focused text messaging was feasible and acceptable. Larger studies will determine the long-term effectiveness of such an approach.
Identifiants
pubmed: 30675374
doi: 10.1186/s40814-019-0395-8
pii: 395
pmc: PMC6332845
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Déclaration de conflit d'intérêts
Ethical approval was granted by the Tufts IRB and all participants provided written informed consent.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Aten Primaria. 2004 Nov 15;34(8):399-405
pubmed: 15546536
Manag Care Interface. 2006 Jul;19(7):31-41
pubmed: 16898343
Am J Hypertens. 2007 Feb;20(2):119-25
pubmed: 17261454
N Engl J Med. 2007 Sep 20;357(12):1221-8
pubmed: 17881753
BMJ. 2012 May 23;344:e3482
pubmed: 22623635
N Engl J Med. 2012 Jul 5;367(1):1-3
pubmed: 22716935
J Med Internet Res. 2012 Nov 21;14(6):e161
pubmed: 23171838
Annu Rev Public Health. 2013;34:431-47
pubmed: 23297657
Am J Prev Med. 2013 Feb;44(2):185-9
pubmed: 23332337
J Diabetes Sci Technol. 2013 May 01;7(3):749-58
pubmed: 23759409
Circulation. 2013 Jul 2;128(1):29-41
pubmed: 23817481
JAMA. 2013 Dec 11;310(22):2395-6
pubmed: 24158428
Ann Intern Med. 2014 Apr 15;160(8):517-25
pubmed: 24733192
Coll Antropol. 2014 Mar;38(1):55-62
pubmed: 24851597
BMC Fam Pract. 2014 Jul 02;15:130
pubmed: 24989986
JAMA. 2015 Sep 22-29;314(12):1255-63
pubmed: 26393848
JAMA. 2015 Oct 20;314(15):1561-2
pubmed: 26501530
Ann Intern Med. 2016 Jan 19;164(2):114-9
pubmed: 26595370
Circulation. 2016 Feb 9;133(6):592-600
pubmed: 26769742
JAMA Intern Med. 2016 Mar;176(3):340-9
pubmed: 26831740
Diabetes Care. 2017 Oct;40(10):1349-1355
pubmed: 28600309
JAMA Intern Med. 2017 Aug 1;177(8):1093-1101
pubmed: 28654972
PLoS Med. 2017 Sep 19;14(9):e1002389
pubmed: 28926573